BI licenses exclusive rights to Hanmi's HM61713 lung cancer candidate; later gives back rights
Executive Summary
Boehringer Ingelheim GMBH licensed exclusive worldwide rights (except in South Korea, China, and Hong Kong) from South Korean firm Hanmi Pharmaceutical Co. Ltd.'s HM61713, a third-generation candidate for epidermal growth factor receptor (EGFR) mutation-positive lung cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice